Literature DB >> 26122033

Wnt Signaling in Rhabdomyosarcoma - A Potential Targeted Therapy Option.

Eleanor Chen1.   

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in the pediatric population and recapitulates many of the phenotypic and biological features of embryonic skeletal muscle. RMS is pathologically characterized by myogenic differentiation arrest. Dysregulation of pathways essential for myogenesis like contribute to the tumorigenesis of RMS. The Wnt signaling pathway is one of the major pathways required for normal myogenesis. Aberrant Wnt signaling has also been demonstrated in many types of cancer. The role of Wnt pathway in the pathogenesis of RMS is beginning to be appreciated. This review will go over current knowledge on biological roles of Wnt pathway in RMS and potential translational application in therapeutics.

Entities:  

Mesh:

Year:  2016        PMID: 26122033     DOI: 10.2174/1389450116666150630110625

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  3 in total

1.  Prohibitin 2 localizes in nucleolus to regulate ribosomal RNA transcription and facilitate cell proliferation in RD cells.

Authors:  Zilong Zhou; Huihan Ai; Kun Li; Xinlei Yao; Wenbin Zhu; Lei Liu; Chunlei Yu; Zhenbo Song; Yongli Bao; Yanxin Huang; Yin Wu; Lihua Zheng; Ying Sun; Guannan Wang; Kewei Ma; Luguo Sun; Yuxin Li
Journal:  Sci Rep       Date:  2018-01-24       Impact factor: 4.379

2.  JARID2 and the PRC2 complex regulate skeletal muscle differentiation through regulation of canonical Wnt signaling.

Authors:  Abhinav Adhikari; Judith Davie
Journal:  Epigenetics Chromatin       Date:  2018-08-17       Impact factor: 4.954

3.  CDK1 and CCNB1 as potential diagnostic markers of rhabdomyosarcoma: validation following bioinformatics analysis.

Authors:  Qianru Li; Liang Zhang; Jinfang Jiang; Yangyang Zhang; Xiaomeng Wang; Qiaochu Zhang; Yang Wang; Chunxia Liu; Feng Li
Journal:  BMC Med Genomics       Date:  2019-12-23       Impact factor: 3.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.